These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15482135)

  • 21. The use of levofloxacin in the treatment of respiratory tract infection.
    Shah PM
    J Chemother; 2000 Oct; 12 Suppl 4():27-31. PubMed ID: 11131957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome.
    Smelov V; Perekalina T; Artemenko N; Smelova N; Ukleeva G; Gorelov A
    Andrologia; 2005 Jun; 37(2-3):61-4. PubMed ID: 16026425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
    Tennenberg AM; Davis NB; Wu SC; Kahn J
    Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levofloxacin, a second-generation fluoroquinolone.
    North DS; Fish DN; Redington JJ
    Pharmacotherapy; 1998; 18(5):915-35. PubMed ID: 9758306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
    George J; Morrissey I
    J Antimicrob Chemother; 1997 Jun; 39(6):719-23. PubMed ID: 9222040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
    Noviello S; Ianniello F; Leone S; Esposito S
    Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expanding role of fluoroquinolones.
    Schaeffer AJ
    Am J Med; 2002 Jul; 113 Suppl 1A():45S-54S. PubMed ID: 12113871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Levofloxacin (Tavanic) in the treatment of corneal ulcers].
    Maĭchuk IuF
    Antibiot Khimioter; 2003; 48(6):16-9. PubMed ID: 14558414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Laboratory and clinical studies on levofloxacin].
    Tanaka K; Iwamoto M; Maesaki S; Koga H; Kohno S; Hara K; Sugawara K; Kaku M; Kusano S; Sakito O
    Jpn J Antibiot; 1992 May; 45(5):548-56. PubMed ID: 1512941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Ryan BM; Mazzucco CE; Lawrence LE; Ho H; Warr G; Barrett JF; Frosco M
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
    Houston AK; Jones RN
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):57-9. PubMed ID: 8026158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levofloxacin for the treatment of respiratory tract infections.
    Torres A; Liapikou A
    Expert Opin Pharmacother; 2012 Jun; 13(8):1203-12. PubMed ID: 22594848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical applications of levofloxacin for severe infections.
    Graninger W; Zeitlinger M
    Chemotherapy; 2004; 50 Suppl 1():16-21. PubMed ID: 15319550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
    Lafredo SC; Foleno BD; Fu KP
    Chemotherapy; 1993; 39(1):36-9. PubMed ID: 8383031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
    Yamakawa T; Mitsuyama J; Hayashi K
    J Antimicrob Chemother; 2002 Mar; 49(3):455-65. PubMed ID: 11864945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection of resistant variants of respiratory pathogens by quinolones.
    Sefton AM; Maskell JP; Williams JD
    Int J Antimicrob Agents; 1999 Jul; 12(2):129-34. PubMed ID: 10418757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial.
    Giannarini G; Mogorovich A; Valent F; Morelli G; De Maria M; Manassero F; Barbone F; Selli C
    J Chemother; 2007 Jun; 19(3):304-8. PubMed ID: 17594926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral ciprofloxacin, ofloxacin, and lomefloxacin as alternatives to intravenous antimicrobial therapy.
    Belliveau P; Nightingale CH; Quintiliani R; Crowe H; Gousee G
    Conn Med; 1993 Aug; 57(8):539-45. PubMed ID: 8243083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.